Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "UPS"

559 News Found

Akums launches high-strength Paracetamol oral suspension 500mg/5ml
News | July 23, 2025

Akums launches high-strength Paracetamol oral suspension 500mg/5ml

Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats


Torrent Pharma launches nutrition supplement powder Shelcal Total
News | July 23, 2025

Torrent Pharma launches nutrition supplement powder Shelcal Total

Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio


FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%
Drug Approval | July 15, 2025

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,


Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects
People | July 14, 2025

Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects

Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.


Panacea Biotec reaches settlement with Apotex
News | July 12, 2025

Panacea Biotec reaches settlement with Apotex

Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension


Apollo AyurVAID launches India’s first ‘Tested Safe’ ayurveda products
News | July 11, 2025

Apollo AyurVAID launches India’s first ‘Tested Safe’ ayurveda products

Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content


INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease
Clinical Trials | July 02, 2025

INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease

Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients


European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME
Drug Approval | June 28, 2025

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME


Thyrocare opens diagnostic lab in Srinagar
News | June 06, 2025

Thyrocare opens diagnostic lab in Srinagar

33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley


Paras Health Gurugram raises alarm over surge in tobacco-related cancers
News | May 31, 2025

Paras Health Gurugram raises alarm over surge in tobacco-related cancers

Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers